Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results from a pan-European study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Amele, S, Peters, L, Rodger, A, Lundgren, J, Rockstroh, J, Matulionyte, R, Leen, C, Jabłonowska, E, Østergaard, L, Bhagani, S, Sarcletti, M, Clarke, A, Falconer, K, Wandeler, G, Domingo, P, Maltez, F, Zaccarelli, M, Chkhartisvili, N, Szlavik, J, Stephan, C, Fonquernie, L, Aho, I & Mocroft, A 2021, 'Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results from a pan-European study', Journal of acquired immune deficiency syndromes (1999), bind 86, nr. 2, s. 248-257. https://doi.org/10.1097/QAI.0000000000002541

APA

Amele, S., Peters, L., Rodger, A., Lundgren, J., Rockstroh, J., Matulionyte, R., Leen, C., Jabłonowska, E., Østergaard, L., Bhagani, S., Sarcletti, M., Clarke, A., Falconer, K., Wandeler, G., Domingo, P., Maltez, F., Zaccarelli, M., Chkhartisvili, N., Szlavik, J., ... Mocroft, A. (2021). Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results from a pan-European study. Journal of acquired immune deficiency syndromes (1999), 86(2), 248-257. https://doi.org/10.1097/QAI.0000000000002541

CBE

Amele S, Peters L, Rodger A, Lundgren J, Rockstroh J, Matulionyte R, Leen C, Jabłonowska E, Østergaard L, Bhagani S, Sarcletti M, Clarke A, Falconer K, Wandeler G, Domingo P, Maltez F, Zaccarelli M, Chkhartisvili N, Szlavik J, Stephan C, Fonquernie L, Aho I, Mocroft A. 2021. Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results from a pan-European study. Journal of acquired immune deficiency syndromes (1999). 86(2):248-257. https://doi.org/10.1097/QAI.0000000000002541

MLA

Vancouver

Author

Amele, Sarah ; Peters, Lars ; Rodger, Alison ; Lundgren, Jens ; Rockstroh, Jϋrgen ; Matulionyte, Raimonda ; Leen, Clifford ; Jabłonowska, Elzbieta ; Østergaard, Lars ; Bhagani, Sanjay ; Sarcletti, Mario ; Clarke, Amanda ; Falconer, Karolin ; Wandeler, Gilles ; Domingo, Pere ; Maltez, Fernando ; Zaccarelli, Mauro ; Chkhartisvili, Nikoloz ; Szlavik, Janos ; Stephan, Christoph ; Fonquernie, Laurent ; Aho, Inka ; Mocroft, Amanda. / Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals : Results from a pan-European study. I: Journal of acquired immune deficiency syndromes (1999). 2021 ; Bind 86, Nr. 2. s. 248-257.

Bibtex

@article{d5cc6ff56e43472f89952741b81ebd78,
title = "Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results from a pan-European study",
abstract = "OBJECTIVES: To investigate the effectiveness, safety, and reasons for premature discontinuation of direct-acting antivirals (DAAs) in a diverse population of HIV/hepatitis C virus (HCV) coinfected individuals in Europe.METHODS: All HIV/HCV coinfected individuals in the EuroSIDA study that started interferon free DAA treatment between January 6, 2014, and January 3, 2018, with ≥12 weeks of follow-up after treatment stop were included in this analysis. Sustained virological response (SVR) was defined as a negative HCV-RNA result ≥12 weeks after stopping treatment (SVR12). Logistic regression was used to explore factors associated with SVR12.RESULTS: 1042 individuals started interferon-free DAA treatment after 1/6/2014 and were included, 862 (82.2%) had a known response to treatment, and 789 [91.5%, 95% confidence interval (CI): 89.7 to 93.4] of which achieved SVR12. There were no differences in SVR12 across regions of Europe (P = 0.84). After adjustment, the odds of achieving SVR12 was lower in individuals that received sofosbuvir/simeprevir ± ribavirin (RBV) [adjusted odds ratio 0.21 (95% CI: 0.08 to 0.53)] or ombitasvir/paritaprevir/dasabuvir ± RBV [adjusted odds ratio 0.46 (95% CI: 0.22 to 1.00)] compared with sofosbuvir/ledipasvir ± RBV. Forty-three (4.6%) individuals had one or more components of their HCV regimen stopped early, most commonly because of toxicity (n = 14); of these 14, 11 were treated with ribavirin. Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n = 15.3%) and was related to treatment with atazanavir and ribavirin.CONCLUSIONS: Our findings from real-world data on HIV/HCV coinfected individuals across Europe show DAA treatment is well tolerated and that high rates of SVR12 can be achieved in all regions of Europe.",
author = "Sarah Amele and Lars Peters and Alison Rodger and Jens Lundgren and Jϋrgen Rockstroh and Raimonda Matulionyte and Clifford Leen and Elzbieta Jab{\l}onowska and Lars {\O}stergaard and Sanjay Bhagani and Mario Sarcletti and Amanda Clarke and Karolin Falconer and Gilles Wandeler and Pere Domingo and Fernando Maltez and Mauro Zaccarelli and Nikoloz Chkhartisvili and Janos Szlavik and Christoph Stephan and Laurent Fonquernie and Inka Aho and Amanda Mocroft",
note = "Copyright {\textcopyright} 2020 Wolters Kluwer Health, Inc. All rights reserved.",
year = "2021",
month = feb,
day = "1",
doi = "10.1097/QAI.0000000000002541",
language = "English",
volume = "86",
pages = "248--257",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

RIS

TY - JOUR

T1 - Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals

T2 - Results from a pan-European study

AU - Amele, Sarah

AU - Peters, Lars

AU - Rodger, Alison

AU - Lundgren, Jens

AU - Rockstroh, Jϋrgen

AU - Matulionyte, Raimonda

AU - Leen, Clifford

AU - Jabłonowska, Elzbieta

AU - Østergaard, Lars

AU - Bhagani, Sanjay

AU - Sarcletti, Mario

AU - Clarke, Amanda

AU - Falconer, Karolin

AU - Wandeler, Gilles

AU - Domingo, Pere

AU - Maltez, Fernando

AU - Zaccarelli, Mauro

AU - Chkhartisvili, Nikoloz

AU - Szlavik, Janos

AU - Stephan, Christoph

AU - Fonquernie, Laurent

AU - Aho, Inka

AU - Mocroft, Amanda

N1 - Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2021/2/1

Y1 - 2021/2/1

N2 - OBJECTIVES: To investigate the effectiveness, safety, and reasons for premature discontinuation of direct-acting antivirals (DAAs) in a diverse population of HIV/hepatitis C virus (HCV) coinfected individuals in Europe.METHODS: All HIV/HCV coinfected individuals in the EuroSIDA study that started interferon free DAA treatment between January 6, 2014, and January 3, 2018, with ≥12 weeks of follow-up after treatment stop were included in this analysis. Sustained virological response (SVR) was defined as a negative HCV-RNA result ≥12 weeks after stopping treatment (SVR12). Logistic regression was used to explore factors associated with SVR12.RESULTS: 1042 individuals started interferon-free DAA treatment after 1/6/2014 and were included, 862 (82.2%) had a known response to treatment, and 789 [91.5%, 95% confidence interval (CI): 89.7 to 93.4] of which achieved SVR12. There were no differences in SVR12 across regions of Europe (P = 0.84). After adjustment, the odds of achieving SVR12 was lower in individuals that received sofosbuvir/simeprevir ± ribavirin (RBV) [adjusted odds ratio 0.21 (95% CI: 0.08 to 0.53)] or ombitasvir/paritaprevir/dasabuvir ± RBV [adjusted odds ratio 0.46 (95% CI: 0.22 to 1.00)] compared with sofosbuvir/ledipasvir ± RBV. Forty-three (4.6%) individuals had one or more components of their HCV regimen stopped early, most commonly because of toxicity (n = 14); of these 14, 11 were treated with ribavirin. Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n = 15.3%) and was related to treatment with atazanavir and ribavirin.CONCLUSIONS: Our findings from real-world data on HIV/HCV coinfected individuals across Europe show DAA treatment is well tolerated and that high rates of SVR12 can be achieved in all regions of Europe.

AB - OBJECTIVES: To investigate the effectiveness, safety, and reasons for premature discontinuation of direct-acting antivirals (DAAs) in a diverse population of HIV/hepatitis C virus (HCV) coinfected individuals in Europe.METHODS: All HIV/HCV coinfected individuals in the EuroSIDA study that started interferon free DAA treatment between January 6, 2014, and January 3, 2018, with ≥12 weeks of follow-up after treatment stop were included in this analysis. Sustained virological response (SVR) was defined as a negative HCV-RNA result ≥12 weeks after stopping treatment (SVR12). Logistic regression was used to explore factors associated with SVR12.RESULTS: 1042 individuals started interferon-free DAA treatment after 1/6/2014 and were included, 862 (82.2%) had a known response to treatment, and 789 [91.5%, 95% confidence interval (CI): 89.7 to 93.4] of which achieved SVR12. There were no differences in SVR12 across regions of Europe (P = 0.84). After adjustment, the odds of achieving SVR12 was lower in individuals that received sofosbuvir/simeprevir ± ribavirin (RBV) [adjusted odds ratio 0.21 (95% CI: 0.08 to 0.53)] or ombitasvir/paritaprevir/dasabuvir ± RBV [adjusted odds ratio 0.46 (95% CI: 0.22 to 1.00)] compared with sofosbuvir/ledipasvir ± RBV. Forty-three (4.6%) individuals had one or more components of their HCV regimen stopped early, most commonly because of toxicity (n = 14); of these 14, 11 were treated with ribavirin. Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n = 15.3%) and was related to treatment with atazanavir and ribavirin.CONCLUSIONS: Our findings from real-world data on HIV/HCV coinfected individuals across Europe show DAA treatment is well tolerated and that high rates of SVR12 can be achieved in all regions of Europe.

U2 - 10.1097/QAI.0000000000002541

DO - 10.1097/QAI.0000000000002541

M3 - Journal article

C2 - 33079903

VL - 86

SP - 248

EP - 257

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -

ID: 61064175